Malignant transformation of melanocytes frequently coincides with loss of E-cadherin expression. Here, we show that loss of E-cadherin leads to induction of nuclear factor kappa B (NFjB) activity in melanoma cell lines. Melanoma cells show constitutively active NFjB, whereas no activity is found in primary melanocytes. After reexpression of E-cadherin in melanoma cells, strong downregulation of NFjB activity was found. Consistently, NFjB activity was induced in primary human melanocytes after inhibition of E-cadherin activity by functionally blocking anti-E-cadherin antibodies. Interestingly, reexpression of E-cadherin-blocked p38 MAPK activity and the p38 MAPK inhibitors SB203580 and SB202190 almost completely prevented NFjB activation in melanoma cells. Furthermore, cytoplasmatic b-catenin induced p38 and NFjB activation in malignant melanoma. To our knowledge, this is the first report suggesting a correlation between E-cadherin and NFjB activity in melanocytes and melanoma cells. In summary, we conclude that loss of E-cadherin and cytoplasmatic b-catenin induces p38-mediated NFjB activation, potentially revealing an important mechanism of tumorigenesis in malignant melanomas.
Introduction
The cell-cell adhesion molecule E-cadherin has been shown to execute important functions in embryogenesis and tissue architecture by forming intercellular junction complexes and establishing cell polarization (Gumbiner et al., 1988) . The extracellular domain of E-cadherin is involved in a molecular zipper mediating cell-cell adhesion, while the cytoplasmic tail is linked to the actin cytoskeleton via catenins (Cowin, 1994; Shapiro et al., 1995) . Owing to its critical function in intercellular adhesion, E-cadherin has also been assumed to act as a tumor suppressor negatively regulating several critical steps of invasion and metastasis. Loss of E-cadherin expression during tumor development was recently observed in a variety of different tumor types including malignant melanomas (Berx et al., 1995 (Berx et al., , 1996 Tamura et al., 1996a, b; Silye et al., 1998; Sanders et al., 1999; Melki et al., 2000; Poser et al., 2001 ). Further, we have shown that inhibition of the expression of the transcriptional repressor snail induced re-expression of Ecadherin in Mel Im melanoma cells (Poser et al., 2001) . Transfection of E-cadherin cDNA into invasive carcinoma cells leads to a significant reduction of their invasive capacity in vitro (Frixen et al., 1991; Vleminckx et al., 1991) , and activation of E-cadherin expression results in growth retardation of tumor cell lines (Watabe et al., 1994) . Recent experiments suggest that E-cadherin is not only involved in cell-cell contact but multiple signalling pathways are activated or repressed by Ecadherin function. One of the most commonly discussed pathway is the b-catenin/LEF/T-cell factor (TCF) signalling cascade (Nollet et al., 1999; Novak and Dedhar, 1999) . Further, other groups could show a regulation of MAP kinases via E-cadherin (Pece and Gutkind, 2000) .
Nuclear factor kappa B (NFkB) is a heterodimeric transcripton factor that is predominantly composed of 65 and 50 kDa subunits of the Rel family. In resting cells, NFkB is mainly retained in the cytoplasm by the inhibitor of NFkB (IkB) family of proteins, which mask the nuclear translocation signal of the transcription factor. Upon stimulation of cells, two defined serine residues in the NH 2 terminus of IkB proteins are phosphorylated triggering their ubiquitination and subsequent degradation by the 26S proteasome. Hereby, the NFkB proteins are released for translocation to the nucleus and induction of kB-dependent genes.
NFkB modulates multiple basic cellular functions like cell growth, differentiation, inflammatory response, and immune response. More recently, NFkB activation has been connected with multiple aspects of oncogenesis, including the control of apoptosis, the cell cycle, differentiation, and cell migration (Baldwin, 2001) . Several reports demonstrated strong and constitutive activity of NFkB in malignant melanoma, possibly through enhanced IkB kinase (IKK) activity and IkB degradation (Shattuck-Brandt and Richmond, 1997; Yang and Richmond, 2001 ). The upstream signalling pathways leading to IKK activity and NFkB activity in malignant melanoma are unknown until today.
In this study, we examined the relationship between the loss of E-cadherin expression and NFkB signalling in malignant melanoma.
Results
One early and tremendous change in the development of malignant melanoma is the loss of E-cadherin expression. Whereas human melanocytes show expression of this cell-cell adhesion molecule, melanoma cells lose E-cadherin but show expression of N-cadherin. Nuclear extracts from malignant melanoma display strong NFkB DNA-binding activity as compared to melanocytes. Accordingly, transient transfection assays and electrophoretic mobility shift assay (EMSA) data showed that NFkB transcriptional and DNA-binding activity is higher in malignant melanoma cell lines than in melanocytes (Figure 1a and b) .
We next examined the interplay between loss of E-cadherin and upregulation of NFkB activity.
To induce E-cadherin expression in melanoma cells, we used two experimental models. The melanoma cell line Mel Im stably transfected with antisense snail cDNA showed induction of E-cadherin expression as previously shown by our group (Poser et al., 2001) . Furthermore, E-cadherin expression in the Mel Im cells was induced by transient transfection of an E-cadherin expression plasmid. Effectiveness of both transfection methods was shown previously (Poser et al., 2001 ) and evaluated by quantitative reverse transcription (RT)-PCR and Western blots for E-cadherin revealing an E-cadherin expression of approximately 50% compared to normal human melanocytes (Figure 2a and b) .
In further experiments, the antisense snail-transfected melanoma cells showed reduction of NFkB DNAbinding activity and transcriptional activity (Figure 3a and c). Moreover, transient E-cadherin overexpression reduced NFkB DNA binding and transcriptional activity (Figure 3b and c). The reduction of NFkB was shown to be dependent on the amount of E-cadherin expression by a dose curve (data not shown). Immunofluorescence staining revealed translocation of p65 from the nucleus to the cytoplasm in the Mel Im as snail clones (re-expressing E-cadherin) in comparison to Mel Im cells (Figure 3d) . Additionally, Western blots show To verify this regulatory effect, primary human melanocytes were treated with an inhibitory antibody against E-cadherin. Interestingly, NFkB DNA-binding activity is induced in conditions where E-cadherin signalling is blocked, whereas the use of control antibodies had no effect on NFkB DNA-binding activity (Figure 4) . Moreover, expression of the endogenous NFkBdependent gene interleukin 8 (IL-8) was reduced in melanoma cells transiently transfected with an Ecadherin expression plasmid, whereas expression of the NFkB-independent gene transcriptional growth factor beta 2 (TGFb2) remained unchanged ( Figure 5 ).
The interplay between E-cadherin and NFkB signalling pathway is unknown. However, it was shown that E-cadherin negatively regulates MAP kinase activity (Pece and Gutkind, 2000) , a pathway that intersects with the NFkB signalling cascade (Vanden Berghe et al., 1998) . Therefore, we speculated that E-cadherin may modulate NFkB activity through the MAP kinase pathway. To verify this hypothesis, we investigated the effect of E-cadherin on the phosphorylation of four members of the MAP kinase family (c-jun NH 2 -terminal kinase (JNK), p42/44ERK1/2, p38) using the wild-type Mel Im cell line (E-cadherin negative) and two cell clones transfected with antisense snail (E-cadherin positive). Furthermore, we analysed the regulation of the protein kinase Akt.
p42ERK2 was expressed and constitutively phosphorylated in melanoma cells, whereas only weak expression and phosphorylation of p44ERK1 was found. p42ERK2 and p44ERK1 phosphorylation remained unchanged in the melanoma cell clones Mel Im as snail 4 and 5 (E-cadherin positive) as well as in Mel Im melanoma cells transiently transfected with Ecadherin ( Figure 6a ). Further, Western blots revealed no regulation of JNK (data not shown) which was further supported by the finding that we found no change of c-jun phosphorylation after re-expression of E-cadherin ( Figure 6b ) was detectable. Additionally, Figure 6c shows that the kinase Akt was not influenced by E-cadherin expression. The analysis of p38 was carried out using a quantitative enzyme-linked immunosorbent assay (ELISA) system and Western blots for phosphorylated and unphosphorylated p38. Marked downregulation of p38 phosphorylation was observed after re-expression of E-cadherin in melanoma cells with the ELISA system ( Figure 6d ). These data are supplemented by the Western blot for p-p38 and as the loading control p38 (Figure 6e ).
To analyse the functional role of p38 MAP kinase on E-cadherin-mediated downregulation of NFkB activity, we used inhibitors of MAP kinases. Interestingly, NFkB transcriptional activity was strongly reduced following inhibition of p38 by SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole) and SB202190 (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole) in Mel Im cells (data not shown), whereas inhibitors against p42/44ERK did not show an effect (PD98059, 2-(2 0 amino-3 0 -methoxyphenyl)-oxanaphthalen-4-one). Further, we investigated whether MAP kinase kinase1 (MEKK1) was involved as an upstream regulating factor but found it not to be involved in p38 regulation by E-cadherin (data not shown).
As loss of E-cadherin is accompanied by free cytoplasmatic b-catenin, we analysed the localization of b-catenin in melanoma tissue by immunohistochemistry and could clearly show strong cytoplasmatic but no membrane staining (data not shown).
Also, immunofluorescence data of Mel Im cells showed cytoplasmatic and not nuclear localization of b-catenin in this cells (Figure 7a ). To trigger this effect of b-catenin in the melanoma cell line Mel Im, we transiently transfected the cells with b-catenin. To check the transfection efficiency, we used the quantitative RT-PCR and immunofluorescence. Figure 8a No effect on p38 and on NFkB activity was observed after transient transfection with a g-catenin expression plasmid. Inhibitors of p38 MAPK (SB203580, SB202190) completely blocked the b-catenin-induced NFkB activation, suggesting that this effect is mediated by p38 MAPK.
Discussion
In this study, we have shown for the first time that strong constitutive activity of NFkB in malignant melanoma correlates with loss of E-cadherin and induction of p38 activation.
NFkB is a key transcription factor activated by several cellular signal transduction pathways. It is of critical importance in regulating cellular processes such as inflammation, host defence, apoptosis and also tumorigenesis. We and others have shown that NFkB is constitutively activated in malignant melanoma as well as in other types of cancer (Huang et al., 2000; Davis et al., 2001; McNulty et al., 2001; Suh et al., 2002) . Strong induction of NFkB in malignant melanoma was previously reported by Yang and Richmond (2001) and Shattuck-Brandt and Richmond (1997) . They showed constitutive IkappaB kinase activity and subsequent decrease in IkappaB a steady-state levels in several melanoma cell lines. However, the molecular mechanisms of constitutive NFkB activation in melanoma and involved upstream signalling pathways remained unclear so far.
In this study, we demonstrated that NFkB activity is associated with the loss of E-cadherin in malignant melanoma. The experiments presented revealed that reexpression of E-cadherin in melanoma cells either by transient transfection of E-cadherin or stable by Figure 4 Gel shift assays to analyse NFkB activity in primary human melanocytes after inhibition of E-cadherin activity. In normal human epidermal melanocytes (NHEM), no NFkB binding to a consensus NFkB-binding site was detectable. After treating the cells with an anti-E-cadherin antibody, which functionally blocks E-cadherin activity, induction of NFkB was found. Anti-IgG and N-cadherin antibodies, respectively, were used as control. No NFkB-binding activity was detectable in control treated NHEMs Figure 5 Expression of IL-8 and TGFb2 in melanoma cells after re-expression of E-cadherin. The expression of IL-8 and TGFb2 was quantified using ELISA systems. Expression was compared between Mel Im cells and the E-cadherin re-expressing Mel Im cells. A reduction of IL-8 expression was seen, whereas no change in TGFb2 expression was found E-cadherin negatively regulates NFjB S Kuphal et al Figure 6 Analysis of MAP kinase activity in melanoma cells before and after re-expression of E-cadherin. ERK1/2 and c-jun expression and activity in the wild-type Mel Im cell line was compared to the two stably antisense snail-transfected cell clones (as snail 4 and 5, right panel) that show re-expression of E-cadherin and to Mel Im cells transiently transfected with E-cadherin (using 0.2 or 0.5 mg plasmid DNA, left panel). (a) ERK2 was detected phosphorylated in melanoma cells, whereas only weak expression and phosphorylation of ERK1 was found. Upregulation of E-cadherin in the melanoma cells led to no changes in ERK1/2 phosphorylation. (b) The phosphorylation of c-jun was not changed comparing Ecadherin-and no E-cadherin (Mel Im)-expressing cells in Western blots for phosphorylated c-jun. The Western blot for unphosphorylated c-jun shows the equal loading of each lane. (c) The phosphorylation of Akt was not changed comparing E-cadherin-and no E-cadherin-expressing cells in a Western blot detecting phosphorylated Akt. b-Actin shows the equal loading of the samples. (d) The analysis of p38 was carried out using an ELISA system. Downregulation of p38 phosphorylation was observed after re-expression of E-cadherin in melanoma cells (as snail 4 and 5) and Ecadherin transient-transfected cells compared to the mock-transfected Mel Im cells (set as 100%). Equaliy in loading was assured by adjusting total protein amount. (e) Western blots were performed in addition to the ELISA analysis. Using an antibody against P-p38, downregulation of the phosphorylation of p38 could be shown. The Western blot of unphosphorylated p38 shows the equal loading of each lane Figure 3f and 5 present enhanced IkB level and reduced expression of NFkB target genes after re-expression of E-cadherin. With the expression of E-cadherin, the amount of the inhibitory protein (IkB) of NFkB increases, the translocation of p65 into the nucleus is prevented and the therefore target genes will not be stimulated by NFkB.
Normal human epithelial melanocytes (NHEM) show no NFkB activity but strong E-cadherin expression. Consistently, we could show that treatment of primary human melanocytes with functionally blocking anti-Ecadherin antibodies led to induction of NFkB activity. This gives the hint for the exceptional role of E-cadherin for the normal human melanocytes and the developing of consequences if E-cadherin expression is lost in melanoma cells.
Previously, other reports demonstrated a correlation between E-cadherin and regulation of MAP kinases. Pece and Gutkind (2000) analysed the activity of MAP kinases p42/p44 in keratinocytes after formation of adherent junctions and revealed remarkable increase in the state of activation. However, in this study, only an unspecific MAPK activity assay was used and consequently no information on the kind of MAPK could be gained. Here, to clarify the regulation of NFkB by E-cadherin in more detail, we started to analyse the influence of E-cadherin on different MAP kinases. Our assays demonstrated strong activity of the MAP kinases in the melanoma cell lines. After retransfection of E-cadherin, our data revealed marked downregulation of p38 MAPK activity in melanoma cells, whereas erk1, erk2, and JNK activity remained unchanged. In accordance to these results, the use of inhibitors of p38 MAPK activity resulted in an almost complete inhibition of NFkB activity and enhanced IkB level.
A possible interaction between p38 MAPK and NFkB was first suggested by Maulik et al. (1998) . They presented evidence that the p38 inhibitor SB203580 prevents NFkB nuclear translocation during ischemic adaptation. Similarly, tumor necrosis factor (TNF)-induced NFkB activity is blocked by p38 inhibitors (Beyaert et al., 1996; Carpentier et al., 1998) . Carter et al. (1999) presented that this regulation is in part dependent on the modulation of the activation of transcription factor IID (TFIID). Further, activation of NFkB can occur due to phosphorylation of the p65 subunit of NFkB. This alternative mechanisms of NFkB activation was discussed by several groups (Vanden Berghe et al., 1998; Madrid et al., 2001) . It has been shown that the cytokines TNF and interleukin-1b lead to phosphorylation of p65 through pathways distinct from induced nuclear translocation. Evidence has been presented that p38 MAP kinase is involved in p65 phosphorylation (Wesselborg et al., 1997; Bergmann et al., 1998) . A study performed by Wang and Richmond (2001) revealed that NFkB is not regulated by the extracellular signalregulated protein kinase (ERK) cascade in malignant melanoma, further supporting our data. These authors also demonstrated the importance of p38 MAPK in activating NFkB, but, in contrast to our experiments, MEKK1 was involved in the analysed MGSA/GRO-ainduced signalling of E-cadherin. The importance of p38 activity for invasion of malignant melanoma cells was determined by Denkert et al. (2002) This study revealed that p38 MAPK inhibition resulted in reduced invasive potential and downregulation of matrix-metalloproteinase 2 (MMP2) expression.
The strong and constitutive activity of the MAPK pathways has been reported previously for malignant melanoma (Englaro et al., 1998; Kortylewski et al., 2001; Denkert et al., 2002) . Here, we further investigated the mechanism leading to p38 MAPK activation in malignant melanoma. In our study, we have shown that b-catenin is involved in p38 MAPK activation. Transient transfection of b-catenin resulted in an enhanced p38 activity, which correlates with the enhancement of NFkB activity. Owing to the loss of E-cadherin, enhanced amounts of free b-catenin can be found in the cytoplasm (Novak and Dedhar, 1999; Orsulic et al., 1999) . Further, Li et al. (2001) recently described stabilization of b-catenin in melanoma cells by Ncadherin. They suggest the stabilization to be controlled by activation of Akt/PBD through N-cadherin-mediated intercellular interaction.
It has been suggested by several reports that the switch from E-cadherin to N-cadherin expression in malignant melanoma has a main impact on tumor development and progression. For example, Li et al. (2001) demonstrated that N-cadherin promotes survival and migration of melanoma cells, processes otherwise being repressed and strictly controlled via E-cadherin.
Striking, NFkB activation is connected to multiple aspects of oncogenesis, including the control of apoptosis and migration and NFkB activity is elevated in malignant melanoma.
To our knowledge, this is the first report showing a correlation between E-cadherin expression and NFkB activity (Figure 8 ). In summary, we conclude that loss of E-cadherin and cytoplasmatic b-catenin induces p38-mediated NFkB activation. These findings potentially reveal an important mechanism of tumor genesis in malignant melanomas.
Materials and methods

Cell lines and cell culture conditions
The melanoma cell line Mel Im has been described in detail previously (Jacob et al., 1998) . It was derived from a metastasis of malignant melanomas. Further, melanoma cell lines Mel Ju, Mel Wei, Mel Juso, Mel Ho, Mel Ei, HTZ-19d, and SK-Mel 28 were used (Jacob et al., 1998) . For tissue culture, the cells were maintained in DMEM supplemented with penicillin (400 U/ml), streptomycine (50 mg/ml), L-glutamine (300 mg/ml), and 10% fetal calf serum (FCS; Sigma, Deisenhofen, Germany) and splitted 1 : 5 every 3 days.
Human primary melanocytes derived from normal skin were cultivated in melanocyte medium MGM-3 (Gibco, Eggenstein, Germany) under a humified atmosphere of 5% CO 2 at 371C. Cells were used between passages 6 and 10 and not later than 3 days after trypsinization. Cells were detached for subcultivation or assay with 0.05% trypsin, 0.04% EDTA in phosphatebuffered saline (PBS).
An inhibitory mouse monoclonal E-cadherin antibody (clone M106, 0.2 mg/ml, Takara, Shiga, Japan) was used in a concentration of 1 mg/ml to analyse the effect of E-cadherin inhibition on primary human melanocytes. The cells were incubated for 24 h. SB203580 and SB202190 (Calbiochem, San Diego, USA) were used as specific inhibitors for p38 MAPK, and PD98059 as a specific inhibitor of p42/44 ERK. Cells were treated for 24 h with a concentration of 10 and 20 mM (for SB203580 and SB202190) or 1 and 10 mM (for PD98059).
Transfection experiments and luciferase measurements
For transient transfections 2 Â 10 5 cells were seeded into each well of a six-well plate and transfected with 0.5 mg plasmid DNA using the lipofectamine plus method (Gibco) according to the manufacturer's instructions. The cells were lysed 24 h after transfection and the luciferase activity in the lysate was quantified by a luminometric assay (Promega Corp., Madison, USA). Transfection efficiency was normalized according to renilla luciferase activity by cotransfecting 0.1 mg of the plasmid pRL-TK (Promega). All transfections were repeated at least four times. For transient transfection, the plasmids NFkB-luc (Promega), pBAT-E-cadherin (generous gift from Gabriele Handschuh (Institute of Pathology, LMU Munich, Germany)), and b-/g-catenin expression vectors (generous gift from Eric Fearon, University of Michigan Medical School, USA) were used.
Further, a panel of Mel Im cell clones was established by stable transfection with an antisense Snail expression plasmid (Poser et al., 2001) under the control of a CMV promoter and cotransfected with the neo-selectable pcDNA3 plasmid (Invitrogen, Groningen, Holland). Transfection was performed using lipofectamine plus (Gibco) according to the manufacturer´s instructions. Transfected cells were cultured under selective conditions using G418 (Sigma) in a concentration of 50 mg/ml. Controls received pcDNA3 alone. After 25 days of selection, individual G418-resistant colonies were subcloned. E-cadherin expression levels of these clones were determined by Western blot analysis of the cell lysates.
Western blotting
Cells (3 Â 10 6 ) were lysed in 200 ml RIPA buffer (Roche, Mannheim, Germany) and incubated for 15 min at 41C. Insoluble fragments were removed by centrifugation at 13 000 r.p.m. for 10 min and the supernatant lysate was immediately shock frozen and stored at À801C. In total, 7-40 mg of RIPA complete cell lysate or nuclear and cytoplasmatic protein fraction were loaded per lane and separated on SDS-PAGE gradient gels (Invitrogen) and subsequently blotted onto a PVDF membrane. After blocking for 1 h with 3% BSA/PBS, the membrane was incubated for 16 h with one of the following antibodies: anti-Erk1/2, anti-P-ERK1/2, antip38, anti-P-SAPK/JNK, anti-IkBa, anti-p-Akt (all from Cell signaling, Beverly, USA), anti-c-jun, and anti-P-c-jun (both from Upstate, Waltham, USA), anti E-cadherin (BD Transduction Laboratories), anti b-actin (Sigma), respectively. We used an alternative blocking method with 5% nonfat dry milk in TBS for the antibodies: anti p65 (Rockland) anti P-p65 (Cell signaling), and anti-P-p38 (Biosource). After three washing steps with PBS or TBS, respectively, the membrane was incubated for 1 h with an alkaline phosphate-coupled secondary anti-mouse or anti rabbit IgG antibody (AP303A, Chemicon, Hofheim, Germany) and then washed again. Finally, immunoreactions were visualized by NBT/BCIP (Sigma) staining.
Immunofluorescence P65 immunofluorescence analysis was performed as described previously (Hellerbrand et al., 1998) . Briefly, 4 Â 10 5 cells were seeded on four-well culture slides (Becton Dickinson Labware, Franklin Lakes, NJ, USA) and fixed after growing for 24 h with ice-cold aceton. Subsequently, slides were washed in PBS and unspecific binding was blocked using 5% BSA/PBS. Then slides were incubated with an anti p65 antibody (1:50; Rockland, Gilbertsville, PA, USA) and anti-b-catenin antibody (Santa Cruz Biotechnology) in 5% BSA/PBS, washed three times with PBS and incubated with FITC-anti-rabbit (1 : 400; DAKO, Glostrup, Denmark), washed again and finally sealed with VectaShild mounting medium (Vector Laboratories, Burlingame, CA, USA) including 1 mg/ml DAPI (Sigma). Slides were viewed using a Zeiss Axioplan epifluorescence microscope (Zeiss, Jena, Germany) and images were taken with a cooled charge-coupled device camera (Photometrics, Tucson, AZ, USA).
p38-ELISA
P-p38 MAPK was measured quantitatively using a phospho ELISA p38 MAPK (pTPY180/182) kit (BioSource International, USA). The ELISA was performed as described by the manufacturer.
IL-8 and TGF-b2 ELISA
IL-8 and TGF-b2 expression were analysed in the supernatant of melanoma cells using ELISAs from Promocell (Heidelberg, Germany) and R&D Systems (Minneapolis, USA), respectively. The assays were performed as described by the manufacturers.
Gel shift experiments
A double-stranded oligomeric binding site for NFkB (5 0 -AGT TGA GGG GAC TTT CCC AGG C-3 0 , Promega) was phospholabelled and used for gel mobility-shift assays. Nuclear extracts were prepared from primary melanocytes and Mel Im cells and gel shifts were performed as described previously (Bosserhoff et al., 1996) . Abbreviations ELISA, enzyme-linked immunosorbent assay; EMSA, electrophoretic mobility shift assay; ERK, extracellular signalregulated protein kinase; IkB (IkappaB), inhibitor of NFkB; IL-8, interleukin 8; JNK, c-jun NH 2 -terminal kinase; MAPK, mitogen-activated protein kinase; Mekk1, MAP kinase kinase1; MMP2, matrix-metalloproteinase 2; NFkB, nuclear factor kappa B; NHEM, normal human epidermal melanocytes; PBS, phosphate-buffered saline; PD98059, 2-(2 0 amino-3 0 -methoxyphenyl)-oxanaphthalen-4-one; PKB, protein kinase B; RT, reverse transcription; SAPK, stress-activated protein kinase; SB202190, 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole; SB203580, 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; TCF, T-cell factor; TGFb2, transcriptional growth factor beta 2.
